Skip to content

US · BRNS · BIOTECHNOLOGY

Barinthus Biotherapeutics plc (BRNS) intrinsic value and stock valuation

$0.74as of 2026-11-21 · Mkt cap 23.29M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Barinthus Biotherapeutics plc DCF and intrinsic value

InvestorsCraft values BRNS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BRNS’s statements →

Barinthus Biotherapeutics plc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Didcot, OX OX11 0DF barinthusbio.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-66.58M
20192025
Free cash flow
-$-48.02M
20192025
Total equity
$74.3M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$15M$800K$44.7M$270K
Operating income-$-54.19M-$-67.97M-$-83.91M-$-4.04M-$-45.22M
Net income-$-66.58M-$-61.07M-$-73.35M$5.34M-$-50.87M
EPSd-$-1.64M-$-1.55M-$-1.91M$139.9K-$-1.37M
Operating cash flow-$-47.98M-$-28.94M-$-50.92M-$-14.43M-$-32.58M
Capital expenditure-$-40K-$-890K-$-5.41M-$-6.14M-$-1.15M
Free cash flow-$-48.02M-$-29.83M-$-56.34M-$-20.57M-$-33.73M
Total assets$98.2M$160.3M$214.5M$270.2M$280.7M
Total debt$11.3M$12M$13M$8.77M$7.22M
Net debt-$-59.17M-$-98.66M-$-129.11M-$-185.61M-$-206.83M
Total equity$74.3M$130.1M$187M$243.2M$252.6M
Cash and short-term investments$70.5M$110.7M$142.1M$194.4M$214.1M
Income statement
20252024202320222021
Revenue$0.00$15M$800K$44.7M$270K
Cost of revenue$5.86M$0.00$0.00$0.00$0.00
Gross profit-$-5.86M$15M$800K$44.7M$270K
Research and development expenses$25.6M$38.3M$41.4M$41.1M$16.4M
Selling, general and administrative expenses$40.8M$29.7M$39.8M$6.39M$25.1M
Other expenses-$-18.06M$15M$3.46M$1.24M$4M
Operating expenses$48.3M$82.9M$84.7M$48.7M$45.5M
Cost and expenses$54.2M$82.9M$84.7M$48.7M$45.5M
Interest income$1.96M$2.68M$2.88M$3.1M$0.00
Interest expense$50K$50K$30K$20K$2.67M
Depreciation and amortization$5.84M$5.8M$5.43M$4.32M$600K
Ebitda-$-62.9M-$-55.37M-$-71.06M$5.19M-$-47.87M
Operating income-$-54.19M-$-67.97M-$-83.91M-$-4.04M-$-45.22M
Total other income/expenses, net-$-14.6M$6.74M$7.39M$4.89M-$-5.92M
Income before tax-$-68.79M-$-61.23M-$-76.52M$850K-$-51.14M
Income tax expense-$-2.18M-$-40K-$-3.08M-$-4.47M-$-30K
Net income-$-66.58M-$-61.07M-$-73.35M$5.34M-$-50.87M
Weighted average shares outstanding$40.5M$39.4M$38.4M$37.3M$37.2M
Weighted average diluted shares outstanding$40.5M$39.4M$38.4M$38.2M$37.2M
Balance sheet
20252024202320222021
Cash and short-term investments$70.5M$110.7M$142.1M$194.4M$214.1M
Net receivables$1.3M$13M$7.94M$18.1M$11.7M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$77.8M$125.7M$156.9M$213M$226.8M
Property, plant and equipment, net$5.16M$11.8M$19.4M$15.7M$9.09M
Goodwill and intangible assets$14.3M$22M$37.3M$40.5M$44.1M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$20.4M$34.6M$57.6M$57.2M$54M
Total assets$98.2M$160.3M$214.5M$270.2M$280.7M
Accounts payable$350K$2.47M$1.6M$3.75M$2.42M
Short-term debt$2.02M$1.92M$1.78M$430K$680K
Deferred revenue$1.4M$1.74M$0.00$0.00$180K
Total current liabilities$10M$15.7M$12.6M$12.2M$11.2M
Long-term debt$9.26M$10.1M$11.2M$8.34M$6.54M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$13.9M$14.5M$14.9M$14.8M$17M
Capital lease obligations$11.3M$12M$13M$8.77M$7.06M
Total liabilities$23.9M$30.2M$27.5M$27M$28.2M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-304.09M-$-237.66M-$-176.59M-$-103.24M-$-108.58M
Accumulated other comprehensive income (loss)-$-15.73M-$-25.87M-$-23.32M-$-33.46M-$-8.49M
Total equity$74.3M$130.1M$187M$243.2M$252.6M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$11.3M$12M$13M$8.77M$7.22M
Net debt-$-59.17M-$-98.66M-$-129.11M-$-185.61M-$-206.83M
Cash flow statement
20252024202320222021
Net income-$-66.46M-$-61.18M-$-73.45M$5.32M-$-51.11M
Depreciation and amortization$5.84M$5.8M$5.43M$4.32M$600K
Stock-based compensation$470K$4.71M$5.05M$9.88M$16.5M
Change in working capital-$-360K$2.6M$6.17M-$-5.52M-$-7.18M
Accounts receivable$6.42M-$-2.35M$5.67M-$-4.67M-$-3.05M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-2.2M$900K-$-3.38M$1.14M-$-3.53M
Net cash provided by operating activities-$-47.98M-$-28.94M-$-50.92M-$-14.43M-$-32.58M
Investments in property, plant and equipment-$-40K-$-890K-$-5.41M-$-6.14M-$-1.15M
Acquisitions, net$450K$0.00$0.00$0.00-$-11.77M
Net cash used for investing activities$420K-$-890K-$-5.41M-$-5.75M-$-12.91M
Common stock issued$0.00$2.16M$2.04M$480K$102.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$0.00$2.16M$1.87M$330K$222.7M
Net change in cash-$-40.55M-$-29.69M-$-52.3M-$-19.67M$170.8M
Cash at end of period$71.9M$112.4M$142.1M$194.4M$214.1M
Operating cash flow-$-47.98M-$-28.94M-$-50.92M-$-14.43M-$-32.58M
Capital expenditure-$-40K-$-890K-$-5.41M-$-6.14M-$-1.15M
Free cash flow-$-48.02M-$-29.83M-$-56.34M-$-20.57M-$-33.73M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Barinthus Biotherapeutics plc

        Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressing a robust portfolio of experimental medicines spanning diverse medical fields. Prominent among these is VTP-300, an immunotherapeutic candidate striving to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. Also in development is VTP-200, a non-surgical therapeutic option aimed at persistent high-risk human papillomavirus (HPV). For autoimmune conditions, VTP-1000 is an autoimmune candidate leveraging the proprietary SNAP-TI platform to treat celiac disease. Additionally, VTP-850 is a next-generation immunotherapeutic designed to address recurrent prostate cancer. Furthermore, the preclinical candidate VTP-1100 utilizes the SNAP-CI platform in its development as a potential treatment for HPV-related cancers. Originally established in 2016 under the name Vaccitech plc, the company rebranded to Barinthus Biotherapeutics plc in November 2023. Its main office is located in Harwell, United Kingdom.

        CEO
        William James Enright
        Employees
        14
        Beta
        -0.40

        Explore

        Frequently asked questions

        What is the intrinsic value of Barinthus Biotherapeutics plc (BRNS)?

        InvestorsCraft does not currently publish an intrinsic value for BRNS. How the IC value is calculated.

        Is BRNS undervalued?

        InvestorsCraft does not publish an undervaluation signal for BRNS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.